EGATEN Drug Patent Profile
✉ Email this page to a colleague
When do Egaten patents expire, and when can generic versions of Egaten launch?
Egaten is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in EGATEN is triclabendazole. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the triclabendazole profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EGATEN?
- What are the global sales for EGATEN?
- What is Average Wholesale Price for EGATEN?
Summary for EGATEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 126 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,269 |
| What excipients (inactive ingredients) are in EGATEN? | EGATEN excipients list |
| DailyMed Link: | EGATEN at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for EGATEN
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for EGATEN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Novartis Pharmaceuticals | Phase 4 |
Pharmacology for EGATEN
US Patents and Regulatory Information for EGATEN
EGATEN is protected by zero US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of EGATEN is ⤷ Sign Up.
This potential generic entry date is based on INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting EGATEN
INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER
Exclusivity Expiration: ⤷ Sign Up
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | EGATEN | triclabendazole | TABLET;ORAL | 208711-001 | Feb 13, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | EGATEN | triclabendazole | TABLET;ORAL | 208711-001 | Feb 13, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
